Background: A comparative study of classical medical texts within Traditional Medicine provides a vital framework for uncovering the origins, development, transmission, and historical significance of healing traditions. This approach highlights a specific culture’s contribution to medical knowledge and reflects the intricate interplay of religion, culture, and philosophical thought embedded in those eras. Aim: To conduct a comparative analysis of the depictions of the “Medicinal Mandala” as described in the first chapter of the “Root Tantra” section in the two classical medical sources Sorig Bumshi and Gyudshi. Materials and Methods: This research examines two foundational Tibetan medical texts—Sorig Bumshi and Gyudshi—using theme-based classification and content analysis methodologies grounded in textual source criticism. Results: The findings confirm that Sorig Bumshi, a Bönpo medical text from the ancient Zhangzhung civilization, was composed earlier. The great translator Byaruzana translated it from the Zhangzhung language, after which Yuthok Yönten Gönpo and collaborators edited, revised, and systematized the text to form Gyudshi, embedding it in Buddhist epistemological frameworks. Conclusions 1. The medicinal mandala of Gyudshi—structured around a central "beautiful medicinal city" surrounded by four directional mountains—demonstrates a refined adaptation of the more expansive, sacred mandala depicted in Sorig Bumshi, which is centered on Olmo Lung Ring, a Bönpo pure land rich in symbolic geography. 2. The numerical values recorded in both texts—particularly the recurring use of 360 and 404—suggest different paradigms in medical theory. Sorig Bumshi embeds these numbers within a Bön cosmological and ritual context (e.g., 360 deities, mountains, and healing lakes), while Gyudshi reinterprets them under Buddhist causal reasoning (e.g., 404 diseases derived from wind, bile, phlegm, and karma). This transformation reflects a shift from Bön to Buddhist medical epistemology through selective integration and doctrinal refinement.

Poly(ADP-ribose) polymerase 1 (PARP1) is a multifunctional protein involved in diverse cellular functions, notably DNA damage repair. Pharmacological inhibition of PARP1 has therapeutic benefits for various pathologies. Despite the increased use of PARP inhibitors, challenges persist in achieving PARP1 selectivity and effective blood-brain barrier (BBB) penetration. The development of a PARP1-specific positron emission tomography (PET) radioligand is crucial for understanding disease biology and performing target occupancy studies, which may aid in the development of PARP1-specific inhibitors. In this study, we leverage the recently identified PARP1 inhibitor, AZD9574, to introduce the design and development of its ¹⁸F-isotopologue ([¹⁸F]AZD9574). Our comprehensive approach, encompassing pharmacological, cellular, autoradiographic, and in vivo PET imaging evaluations in non-human primates, demonstrates the capacity of [¹⁸F]AZD9574 to specifically bind to PARP1 and to successfully penetrate the BBB. These findings position [¹⁸F]AZD9574 as a viable molecular imaging tool, poised to facilitate the exploration of pathophysiological changes in PARP1 tissue abundance across various diseases.

[摘 要] 目的：探究野生型水疱性口炎病毒印第安纳株（VSV-IN）对小鼠三阴性乳腺癌4T1细胞移植模型小鼠的免疫调节及肿瘤转移的影响。方法：VSV以MOI=1、MOI=10、MOI=100感染4T1细胞12、24、48 h后，CCK-8法检测4T1细胞死亡率，划痕愈合实验检测细胞迁移能力，qPCR检测细胞中E-cadherin、MMP-2、MMP-9 mRNA的表达。于雌性BALB/c小鼠脂肪垫接种1×106个/mL的4T1细胞0.1 mL，构建4T1细胞荷瘤小鼠模型，待小鼠肿瘤体积达200 mm3，分别向移植瘤内注射PBS、紫杉醇（TAX）（15 mg/kg）、VSV-IN（1×106 pfu/只），每周1次。给药4次后，处死小鼠、剥离完整移植瘤组织，测量肿瘤体积及质量，肺组织病理切片经H-E染色后观察肿瘤肺部转移结节，流式细胞术检测脾组织中T细胞亚群比例，ELISA法检测小鼠血清IL-6及TNF-α水平，利用GEPIA在线分析乳腺肿中迁移相关蛋白mRNA的表达，免疫组化法检测肿瘤中MMP-2、MMP-9与E-cadherin的表达，利用蛋白-蛋白对接技术预测VSV-IN的G蛋白、M蛋白与ERK2、E-cadherin的亲和力。结果：经MOI=10、100的VSV-IN处理48 h后，4T1细胞死亡率显著高于对照组（均P<0.01）；与对照组相比，VSV-IN组（MOI=10）细胞迁移率明显降低（P<0.01），MMP-9 mRNA的相对表达量明显降低（P<0.05）；与对照组小鼠相比，VSV-IN组移植瘤生长较对照组减缓且终点体积显著减小（P<0.05），VSV-IN组小鼠肺转移结节数量显著减少[（12.86±1.86） vs （24±3.67）个，P<0.01]，脾内CD4+ T、CD8+ T细胞比例显著升高（均P<0.05），血清TNF-α、IL-6含量显著升高（均P<0.01）；GEPIA分析发现在乳腺癌中E-cadherin、MMP-9表达水平均高于癌旁组织（P<0.05）；VSV-IN组小鼠肿瘤细胞内MMP-9表达明显低于对照组（P<0.05）；VSV-IN的G、M蛋白与ERK2的结合自由能分别为–11.7 kcal/mol、–6.4 kcal/mol。结论：野生型VSV-IN可抑制4T1细胞荷瘤小鼠的移植瘤生长及转移，这可能与其促进抗肿瘤免疫及调控迁移相关蛋白表达有关。

[摘 要] 目的：探究连翘苷（Phi）通过调控Hippo/YAP信号通路对结肠癌LS180细胞增殖、迁移和侵袭的影响。方法：用不同浓度（0、5、10、20、40、80 µmol/L）的Phi处理人结肠癌LS180细胞，MTT法检测24、48 和72 h时的细胞活力。将LS180细胞分为对照组、Phi-L（5 µmol/L Phi）组、Phi-M（10 µmol/L Phi）组、Phi-H（20 µmol/L Phi）组、Phi-H+YAP抑制剂维替泊芬（VP）组（20 µmol/L Phi+5 µmol/L VP），各组均处理24 h。EdU法检测Phi对各组细胞增殖的影响，划痕愈合实验、Transwell小室法分别检测Phi对细胞迁移和侵袭的影响，免疫荧光法和WB法检测Phi对细胞Ki-67表达率和LATS1、YAP和p-YAP、MMP-2、MMP-9、E-cadherin、N-cadherin表达的影响。构建LS180细胞移植瘤裸鼠模型，观察Phi对移植瘤体积和质量的影响，免疫荧光法和WB法检测移植瘤组织中Ki-67表达率和LATS1、YAP和p-YAP蛋白的表达水平。结果：与对照组比较，Phi-L、Phi-M和Phi-H组LS180细胞EdU阳性率、划痕愈合率、侵袭细胞数、Ki-67阳性率、MMP-2、MMP-9、N-cadherin表达均显著降低（均P<0.05），E-cadherin、LATS1和p-YAP/YAP表达均显著升高（均P<0.05）；同时使用VP则部分逆转了Phi对LS180细胞增殖、迁移与侵袭的抑制作用（均P<0.05）。Phi显著抑制裸鼠移植瘤生长，与对照组比较，Phi组裸鼠移植瘤体积、质量和Ki-67阳性率均显著降低（均P<0.05），LATS1和p-YAP/YAP水平均显著升高（均P<0.05）。结论：Phi可能通过激活Hippo/YAP信号通路抑制结肠癌LS180细胞的恶性生物学行为。

[摘 要] 目的：探讨精氨酸-甘氨酸-天冬氨酸（RGD）修饰对肿瘤抑素19肽（T-19）抗肝癌活性的影响，比较分析T-19及RGD修饰的T-19（RGD-T-19）对肝癌SK-Hep-1细胞增殖、侵袭和迁移能力的影响。方法：用Fmoc固相法合成T-19及RGD-T-19，用高效液相色谱仪和质谱进行分离、鉴定。常规培养SK-Hep-1细胞，用0、50、100、150、200、250 mg/mL的T-19及RGD-T-19分别处理细胞，分为0 mg/mL（对照）组、50 mg/mL组、100 mg/mL组、150 mg/mL组、200 mg/mL组、250 mg/mL组。CCK-8法、克隆形成实验、划痕愈合实验和Tanswell小室实验、WB法和qPCR法分别检测SK-Hep-1细胞的增殖、迁移、侵袭能力，以及环氧合酶-2（COX-2）、基质金属蛋白酶-2（MMP-2）、MMP-9、组织基质金属蛋白酶抑制剂-1（TIMP-1）、TIMP-2蛋白和MMP-1、MMP-2 mRNA的表达。结果：经质谱鉴定，用Fmoc固相法合成的T-19及RGD-T-19纯度高。T-19和RGD-T-19均能显著抑制SK-Hep-1细胞的增殖、迁移、侵袭能力，抑制COX-2蛋白、MMP-2和MMP-9蛋白及mRNA的表达、促进TIMP-1、TIMP-2蛋白的表达（P < 0.05, P < 0.01, P < 0.001），RGD-T-19的抑制或促进效应均明显强于T-19（均P < 0.05）。结论：利用Fmoc固相法合成了纯度高、活性好的T-19及RGD-T-19，两种肽均能抑制SK-Hep-1细胞增殖、侵袭和迁移能力，RGD-T-19作用明显强于T-19。

Objective:b> To clarify the values of autotaxin (ATX) in patients with primary biliary cholangitis (PBC) and PBC-related hepatocellular carcinoma (HCC). Methods:b> 179 patients with PBC were selected from prospective cohorts of autoimmune liver diseases at the time of first diagnosis of PBC in Department of Hepatology, the Fifth Medical Center of PLA General Hospital, from January 2016 to January 2018, all patients with PBC received UDCA therapy, primary endpoint was event of HCC, the follow-up period was censored at the date of HCC. The relationship between level of ATX and clinical features in patients with PBC and its potential value in predicting disease progression and PBC-related HCC were analyzed. Results:b> The ATX level in the peripheral blood of patients with PBC was significantly higher than that of alcoholic liver cirrhosis(ALC) (t = 3.278, P = 0.001) and healthy controls(HC) (t = 6.594, P < 0.001), however, when comparing PBC to non-PBC related HCC, no significant difference was found between the groups(t=-0.240, P = 0.811). Consistent with peripheral blood levels, histochemical staining indicated that ATX in the liver of patients with PBC was significantly higher than that of HC (Z=-3.633, P < 0.001) and ALC (Z=-3.283, P < 0.001), and the expression of ATX in PBC with advanced histological stage was significantly higher than PBC with early stage (Z=-2.018, P = 0.034). The baseline ATX level in PBC patients without developing to HCC during follow-up had significant difference to patients with developing to HCC (228.451 ± 124.093 ng/ml vs 301.583 ± 100.512 ng/ml, t = 2.339, P = 0.021). The result in multivariate logistic regression analysis showed that ATX were independent predictors of PBC related HCC(OR 1.245, 95%CI 1.097-1.413). The optimal critical value of peripheral blood ATX level at baseline for predicting HCC was 235.254 ng/ml, with the cut-off value of 0.714 in AUC of the ROC (95% CI was 0.597~ 0.857), sensitivity and specificity were 84.6% and 59.0%, respectively. Conclusion:b> ATX level was significantly higher in PBC patients over controls, and it's concentration was correlated with UDCA efficacy and fibrosis stage. ATX has potential values in predicting disease progression and PBC-related HCC.

Purinergic P2Y Receptor Antagonists ; Consensus ; Cardiovascular System ; Cardiology ; Asia

<b>Objective:b> To investigate the clinicopathological features of glomuvenous malformation (GVM). <b>Methods:b> Thirty-one cases of GVM diagnosed at the Henan Provincial People's Hospital from January 2011 to December 2021 were collected. Their clinical and pathological features were analyzed. The expression of relevant markers was examined using immunohistochemistry. The patients were also followed up. <b>Results:b> There were 16 males and 15 females in this study, with an average age of 11 years (range, 1-52 years). The locations of the disease included 13 cases in the limbs (8 cases in the upper limbs, 5 cases in the lower limbs), 9 cases in the trunks, and 9 cases in the foot (toes or subungual area). Twenty-seven of the cases were solitary and 4 were multifocal. The lesions were characterized by blue-purple papules or plaques on the skin surface, which grew slowly. The lumps became larger and appeared to be conspicuous. Microscopically, GVM mainly involved the dermis and subcutaneous tissue, with an overall ill-defined border. There were scattered or clustered irregular dilated vein-like lumens, with thin walls and various sizes. A single or multiple layers of relatively uniform cubic/glomus cells were present at the abnormal wall, with scattered small nests of the glomus cells. The endothelial cells in the wall of abnormal lumen were flat or absent. Immunohistochemistry showed that glomus cells strongly expressed SMA, h-caldesmon, and collagen IV. Malformed vascular endothelial cells expressed CD31, CD34 and ERG. No postoperative recurrence was found in the 12 cases. <b>Conclusions:b> GVM is an uncommon type of simple venous malformation in the superficial soft tissue and different from the classical glomus tumor. Morphologically, one or more layers of glomus cells grow around the dilated venous malformation-like lumen, which can be combined with common venous malformations.
Male ; Female ; Humans ; Child ; Glomus Tumor/surgery* ; Endothelial Cells/pathology* ; Paraganglioma, Extra-Adrenal/pathology* ; Immunohistochemistry

Humans ; Carcinoma, Verrucous/pathology* ; Carcinoma, Squamous Cell/pathology* ; Bone Neoplasms ; Toes/pathology* ; Skin Neoplasms/pathology*

Humans ; Child ; Pulmonary Blastoma/pathology* ; Lung Neoplasms/pathology*